Navigation Links
Life Technologies Announces First Quarter 2013 Results
Date:5/2/2013

CARLSBAD, Calif., May 2, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced results for its first quarter ended March 31, 2013.  Revenue for the first quarter was $963 million, an increase of 2.5 percent over the $939 million reported for the first quarter of 2012.  Excluding the impact of currency, revenue growth for the quarter was 4.4 percent compared to the same period of the prior year.

"We had a successful start to the year with strength across our Applied Sciences and Genetic Analysis business groups, including double digit growth in both our Bioproduction and Forensics businesses, which drove revenues and earnings growth above our guidance expectations," said Gregory T. Lucier, chairman and chief executive officer of Life Technologies.  "Our end markets remained in line with our expectations, with strength in emerging markets and across much of Asia, and continued cautious spending in the United States and Europe, as expected.

"During the quarter, we continued our rapid pace of innovation with new bioinformatics tools for Ion Torrent and software for our synthetic biology business.  We also continued to execute against our strategy to expand in growth and emerging markets as we entered into new collaborations in stem cells, Rapid DNA products, and acquired our reagent distributor in South Korea."

Lucier continued, "On April 15, Life Technologies and Thermo Fisher Scientific announced that the two companies had signed a definitive agreement under which Thermo Fisher will acquire Life for $76.00 in cash per fully diluted common share, or approximately $13.6 billion. We look forward to joining forces with the outstanding team at Thermo Fisher, which shares our commitment to customers, employees and shareholders."

Life Technologies reported results compared to the quarter ended March 31, 2012.  Results are non-GAAP unless indicated otherwise. A full reconciliation of the non-GAAP measures to GAAP can be found in the tables of today's press release.

Analysis of First Quarter 2013 Results

  • First quarter revenue increased 2.5 percent over the prior year, or 4.4 percent excluding the impact of currency.  Revenue growth for the quarter was driven by strong sales from the Ion Torrent, Bioproduction and Forensics businesses, partially offset by expected declines in SOLiD® sales and lower Research Consumables and capital equipment sales primarily due to the expected slowdown in the U.S. as the threat of sequestration impacted customer buying patterns.
  • Gross margin in the first quarter was 66.2 percent, approximately 40 basis points lower than the same period of the prior year. Gross margin was negatively impacted by a higher mix of Ion Torrent instrument sales, Bioproduction sales and unfavorable currency rates, partially offset by manufacturing productivity and royalties including licensing agreements.
  • Operating margin was 29.4 percent in the first quarter, approximately 80 basis points lower than the same period of the prior year. Operating margin was primarily impacted by lower gross margin and planned investments in emerging markets and molecular diagnostics.
  • The tax rate was 26.2 percent for the first quarter.  
  • First quarter EPS increased 8 percent to $1.07.  
  • Diluted weighted shares outstanding were 174.5 million in the first quarter, a decrease of 8.6 million shares over the prior year.  The decrease was a result of the company's share repurchase program, partially offset by shares issued for employee stock plans.  The company repurchased $105 million or 2 million shares in the first quarter.
  • Cash flow from operating activities for the first quarter was $135 million. First quarter capital expenditures were $24 million, offset by $37 million of cash proceeds from the sale of assets, resulting in free cash flow of $148 million.  The company ended the quarter with $293 million in cash and short-term investments.
  • Business Group and Regional Highlights

  • Research Consumables revenue was $409 million in the first quarter, a decrease of 3 percent compared to the prior year.  Excluding the impact from currency, revenue for the business group declined 1 percent. The decline in growth for the quarter was primarily driven by cautious spending in the U.S. and Europe and a tough comparison to prior year in Japan, which benefited from stimulus spending in Q1 2012.
  • Genetic Analysis revenue was $365 million in the first quarter, an increase of 3 percent over the same period last year. Excluding the impact from currency, revenue increased 5 percent. Growth for the quarter was primarily driven by an increase in our Ion Torrent business and royalties including licensing agreements, partially offset by lower CE instrument sales and an expected decline in SOLiD product sales.
  • Applied Sciences revenue was $189 million in the first quarter, an increase of 17 percent over the same period last year. Excluding the impact from currency, revenue increased 19 percent. Growth for the quarter was primarily driven by sales in Bioproduction and Forensics products.
  • Regional revenue growth rates excluding currency for the first quarter compared to the same quarter of the prior year were as follows: the Americas grew 5 percent, Europe grew 3 percent, Asia Pacific grew 10 percent and Japan grew 1 percent.  The Americas benefited from increased sales in Ion Torrent, Forensics, Bioproduction and higher royalties including licensing agreements.  Europe saw growth in Forensics and Bioproduction, offset by lower Research Consumables.  Asia Pacific grew across all business groups primarily due to Ion Torrent, Research Consumables, and Bioproduction.  Japan growth was primarily due to Ion Torrent and Bioproduction sales, offset by lower sales from government stimulus programs that took place in the same period last year.
  • OutlookThe Company anticipates revenue in the range of $950 million to $955 million and non-GAAP diluted earnings per share in the range of $0.94 to $0.97 for the quarter ending June 30, 2013, due to the impact from the fluctuations in currency rates, and the timing of operating expenses and larger deals compared to the guidance provided on February 4, 2013. Based on March 31, 2013 rates, currency is expected to have a negative impact of $62 million to revenue and a negative $0.15 impact to non-GAAP EPS for the full year.

    Conference CallsGiven the recent announcement that Life Technologies and Thermo Fisher have entered into a definitive merger agreement under which Thermo Fisher will acquire all of the outstanding shares of Life Technologies for $76.00 per share in cash, the Company will no longer hold conference calls for its quarterly and annual earnings. The transaction, which is expected to close early in 2014, is subject to a Life shareholder vote and satisfying customary closing conditions, including regulatory approvals.

    About Life Technologies Life Technologies Corporation (NASDAQ:  LIFE) is a global biotechnology company that is committed to providing the most innovative products and services to leading customers in the fields of scientific research, genetic analysis and applied sciences. With a presence in more than 180 countries, the company's portfolio of 50,000 end-to-end solutions are secured by more than 5,000 patents and licenses that span the entire biological spectrum -- scientific exploration, molecular diagnostics, 21st century forensics, regenerative medicine and agricultural research. Life Technologies has approximately 10,000 employees and had sales of $3.8 billion in 2012. Visit us at our website: http://www.lifetechnologies.com.

    Safe Harbor Statement Certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and Life Technologies intends that such forward-looking statements be subject to the safe harbor created thereby. Forward-looking statements may be identified by words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," or words of similar meaning and include, but are not limited to, statements about the expected future business and financial performance of the company and statements regarding the proposed acquisition of Life Technologies by Thermo Fisher. Such forward-looking statements include, but are not limited to, statements relating to financial projections, including revenue and pro forma EPS projections; success of acquired businesses, including cost and revenue synergies; development and increased flow of new products; leveraging technology and personnel; advanced opportunities and efficiencies; opportunities for growth; expectations of prospective new standards, new delivery platforms, and new selling specialization and effectiveness; plans and prospects for the company; corporate strategy and performance; and the expected timetable for completing the transaction with Thermo Fisher. A number of the matters discussed in this press release and presentation that are not historical or current facts deal with potential future circumstances and developments, including future research and development plans. The discussion of such matters is qualified by the inherent risks and uncertainties surrounding future expectations generally and other factors that could cause actual results to differ materially from future results expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to:  volatility of the financial markets; and the risks that are described from time to time in Life Technologies' reports filed with the SEC. This press release and presentation speaks only as of its date, and the company disclaims any duty to update the information herein.

    All products referenced are for Research Use Only and not intended for use in diagnostic procedures, unless otherwise noted.

    Non-GAAP MeasurementsThis discussion includes certain financial information which constitutes "non-GAAP financial measures" as defined by the SEC.  The GAAP measures which are most directly comparable to these measures, as well as a reconciliation of these measures with the most directly comparable GAAP measures, can be found at on the Investor Relations portion of the company's website at www.lifetechnologies.com.

    Additional Information and Where to Find ItThis communication may be deemed to be solicitation material in respect of the proposed acquisition of Life Technologies by Thermo Fisher. In connection with the proposed acquisition, Life Technologies intends to file relevant materials with the SEC, including Life Technologies' proxy statement in preliminary and definitive form. Stockholders of Life Technologies are urged to read all relevant documents filed with the SEC, including Life Technologies' definitive proxy statement, because they will contain important information about the proposed transaction. Investors and security holders are able to obtain the documents (once available) free of charge at the SEC's web site, http://www.sec.gov, or for free from Life Technologies by contacting investor relations at (760) 603-7208 or ir@lifetech.com. Such documents are not currently available.

    Participants in SolicitationThermo Fisher and its directors and executive officers, and Life Technologies and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from the holders of Life Technologies common stock in respect of the proposed transaction. Information about the directors and executive officers of Thermo Fisher is set forth in its proxy statement for Thermo Fisher's 2013 Annual Meeting of stockholders, which was filed with the SEC on April 9, 2013. Information about the directors and executive officers of Life Technologies is set forth in the proxy statement for Life Technologies' 2013 Annual Meeting of stockholders, which was filed with the SEC on March 15, 2013. Investors may obtain additional information regarding the interest of such participants by reading the proxy statement regarding the acquisition (once available).

    (Logo:  http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

    Investor and Financial ContactCarol Cox
    Investor Relations
    (760) 603-7208
    ir@lifetech.comLIFE TECHNOLOGIES CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONSFor the three months ended March 31, 2013For the three months ended March 31, 2012(in thousands, except per share data)(unaudited)Revenues$
    962,512$
    939,114Cost of revenues

    326,014313,681Purchased intangibles amortization

    72,38072,106Gross profit

    564,118553,327Gross margin

    58.6%58.9%Operating expenses:Selling, general and administrative

    271,216253,398Research and development

    83,54688,598Business consolidation costs

    26,68914,266Total operating expenses

    381,451356,262Operating income

    182,667197,065Operating margin

    19.0%21.0%Interest income

    471764Interest expense

    (29,365)(35,738)Other expense, net

    (2,476)(5,716)Total other expense, net

    (31,370)(40,690)Income from operations before provision for income taxes

    151,297156,375Income tax provision

    (30,188)(23,736)Net income

    121,109132,639Net loss attributable to non-controlling interests

    87-Net income attributable to controlling interest$
    21,196$
    32,639Effective tax rate 

    20.0%15.2%Add back interest expense for subordinateddebt, net of tax

    -12Numerator for diluted earnings  per share$
    21,196$
    32,651Earnings per common share:Basic earnings per share attributable to controlling interest$
    .71$
    .74Diluted earnings per share attributable to controlling interest$
    .69$
    .72Weighted average shares used in per share calculation:Basic170,807178,873Diluted

    174,481183,113 

     LIFE TECHNOLOGIES CORPORATIONITEMIZED RECONCILIATION BETWEENGAAP AND NON-GAAP NET INCOMEFor the three months ended
    March 31, 2013For the three months ended March 31, 2012(in thousands, except per share data)(unaudited)GAAP net income $
    21,109$
    32,639Non-GAAP revenue AdjustmentsPurchase accounting related adjustments 

    341364Charges on a discontinued product

    -(457)Total Non-GAAP revenue Adjustments

    341

    (1)

    (93)

    (1)Non-GAAP cost of revenues and purchased intangible AdjustmentsPurchased intangibles amortization

    72,38072,106Purchase accounting related adjustments

    733-Licensing settlement

    -(169)Total Non-GAAP cost of revenues and purchased intangible Adjustments

    73,113

    (2)

    71,937

    (2)Non-GAAP Operating Expense AdjustmentsPurchase accounting related adjustments 

    505927Business consolidation costs

    26,68914,266Licensing settlement

    -(934)Total Non-GAAP Operating Expense Adjustments

    27,194

    (3)

    14,259

    (3)Non-GAAP Other Expense AdjustmentsNoncash interest expense charges 

    -5,382Other expense

    -5,297Total Non-GAAP Other Expense Adjustments

    -10,679

    (4)Non-GAAP Income Tax Provision AdjustmentsIncome tax adjustments

    (35,696)(48,076)Total Non-GAAP Income Tax Provision Adjustments

    (35,696)

    (5)

    (48,076)

    (5)Non-GAAP Net Income$
    86,061$
    81,345Non-GAAP loss attributable to non-controlling interest

    87

    (6)

    -Non-GAAP Net Income Attributable to Controlling Interest$
    86,148$
    81,345Add back of interest expense for subordinated debt, net of tax

    -12Non-GAAP Numerator for diluted earnings per share$
    86,148$
    81,357Non-GAAP Earnings per common share:Basic earnings per share attributable to controlling interest$
    .09$
    .01Diluted earnings per share attributable to controlling interest$
    .07$
    .99Weighted average shares used in per share calculation:Basic170,807178,873Diluted174,481183,113 Summary of Reconciliation between GAAP and Non-GAAP Net IncomeFor the three months ended March 31, 2013, Non-GAAP earnings resulted in total revenue of $962.9 million, gross profit of $637.6 million with gross margin of 66.2%, operating profit of $283.3 million with operating margin of 29.4%, and an income tax provision of $65.9 million with the Non-GAAP effective tax rate of 26.2% with the above adjustments.For the three months ended March 31, 2012, Non-GAAP earnings resulted in total revenue of $939.0 million, gross profit of $625.2 million with gross margin of 66.6%, operating profit of $283.2 million with operating margin of 30.2%, and an income tax provision of $71.8 million with the Non-GAAP effective tax rate of 28.4% with the above adjustments.Notes(1)

    Add back purchased deferred revenue of $0.3 million and $0.4 million for the three months ended March 31, 2013 and 2012, respectively. Adjust for revenue related to a discontinued product of $0.5 million for the three months ended March 31, 2012.(2)

    Add back amortization of purchased intangibles of $72.4 million and amortization of a fair value inventory write-up of $0.8 million, offset by contingent consideration remeasurement of $0.1 million for the three months ended March 31, 2013. Add back amortization of purchased intangibles of $72.1 million and adjust for royalty fees and compensation costs of $0.2 million as a result of a licensing settlement for the three months ended March 31, 2012.(3)

    Add back depreciation of purchase accounting property, plant, and equipment revaluation of $0.5 million for the three months ended March 31, 2013. Add back depreciation of purchase accounting property, plant, and equipment revaluation of $0.9 million, offset by compensation costs of $0.9 million as a result of licensing settlement for the three months ended March 31, 2012. Add back business consolidation costs including restructuring and integrating acquired entities, aligning acquired and existing operations through business transformation activities and costs associated with divesting entities of $26.7 million and $14.3 million for the three months ended March 31, 2013 and 2012, respectively. (4)

    Add back charges associated with a divestiture activity of $5.3 million, charges related to non-cash interest expense for senior convertible debts of $1.7 million and the extinguishment of a line of credit facility of $3.7 million for the three months ended March 31, 2012. (5)

    Non-GAAP tax adjustment due to the exclusion of the aforementioned business combination related charges, non cash charges, and one-time costs which are not indicative of the profitability or cash flows of the Company's ongoing or future operations. These deductions produce a GAAP only tax benefit which is added back for Non-GAAP presentation.(6)

    Non-GAAP net loss attributable to non-controlling interest, net of tax benefit.The Company reports Non-GAAP results which excludes costs that are not indicative of the profitability or cash flows of the Company's ongoing or future operations. Such costs are restructuring cost, business transformation expenses, amortization and depreciation of deferred revenue, intangibles assets, and fixed assets, and revaluation charges for inventories, contingent consideration liabilities, asset impairments, and in process research and development expenses, incurred as a result of business combinations as well as the impact from the divestiture and discontinuance of product lines. The Company also excludes noncash interest expense associated with convertible debt bifurcation and noncash charges associated with non-controlling interests. In addition, the Company excludes one-time costs including the early repayment of debt and the associated impacts, and the impact of certain settlements in order to provide a supplemental comparison of the results of operations. LIFE TECHNOLOGIES CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSFor the three monthsended March 31,(in thousands)(unaudited)20132012Net income$ 121,109$  132,639Add back amortization and share-based compensation

    92,82092,962Add back depreciation

    30,81331,459Balance sheet changes

    (93,055)(62,939)Other noncash adjustments

    (16,968)(90,205)Net cash provided by operating activities

    134,719103,916Capital expenditures

    (23,606)(25,334)Proceeds from sale of assets 

    36,729328Free cash flow147,84278,910Net cash used in investing activities

    (43,511)(39,417)Net cash used in financing activities

    (95,346)(663,372)Effect of exchange rate changes on cash

    (2,741)4,129Net (decrease) increase in cash and cash equivalents$
    ,244$ (619,750) 

     LIFE TECHNOLOGIES CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETSMarch 31,December 31,(in thousands)20132012ASSETS (unaudited) Current assets:Cash and short-term investments

    $
    292,612$
    276,369Trade accounts receivable, net of allowance for doubtful accounts

    691,679697,228Inventories

    407,455403,488Prepaid expenses and other current assets

    277,716248,154Total current assets

    1,669,4621,625,239Long-term assets

    6,869,5867,012,826Total assets

    $
    8,539,048$
    8,638,065LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Current portion of long-term debt

    $
    4,048$
    253,214Short-term borrowings

    324,004100,000Accounts payable, accrued expenses and other current liabilities

    743,064839,137Total current liabilities

    1,071,1161,192,351Long-term debt

    2,068,9792,060,855Other long-term liabilities

    712,632731,396Stockholders' equity

    4,686,3214,653,463Total liabilities and stockholders' equity

    $
    8,539,048$
    8,638,065


    '/>"/>
    SOURCE Life Technologies Corporation
    Copyright©2012 PR Newswire.
    All rights reserved


    Related biology technology :

    1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
    2. UV Flu Technologies Expands Its International Footprint
    3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    4. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
    5. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
    6. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
    7. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
    8. Animal Biotechnology - Technologies, Markets and Companies
    9. Gene Therapy - Technologies, Markets and Companies
    10. Biomarkers - Technologies, Markets and Companies
    11. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
    (Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
    (Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
    (Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
    Breaking Biology Technology:
    (Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
    (Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
    (Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
    Breaking Biology News(10 mins):